Formulary Controversy

Target entity: Formulary Controversy
Context triple: [Unigenitus Dei Filius, relatedTo, Formulary Controversy]

• A. 340B Drug Pricing Program
  The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
• B. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• C. Prescription Drug Marketing Act
  The Prescription Drug Marketing Act is a U.S. federal law that regulates the distribution and marketing of prescription drugs to ensure their safety, effectiveness, and integrity within the pharmaceutical supply chain.
• D. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• E. Medicaid Drug Rebate Program
  The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Formulary Controversy
Target entity description: The Formulary Controversy was a 17th-century theological and political dispute within the French Catholic Church over the required acceptance of an anti-Jansenist doctrinal formula, pitting Jansenist sympathizers against royal and papal authorities.

• A. 340B Drug Pricing Program
  The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
• B. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• C. Prescription Drug Marketing Act
  The Prescription Drug Marketing Act is a U.S. federal law that regulates the distribution and marketing of prescription drugs to ensure their safety, effectiveness, and integrity within the pharmaceutical supply chain.
• D. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• E. Medicaid Drug Rebate Program
  The Medicaid Drug Rebate Program is a U.S. federal initiative that requires drug manufacturers to provide rebates to state Medicaid programs in exchange for Medicaid coverage of their outpatient prescription drugs, helping control costs for the program.
• F. None of above. chosen